. "Polonyov\u00E1, E." . "Anal\u00FDza nemocn\u00FDch s myelodysplastick\u00FDm syndromem (MDS) s delec\u00ED dlouh\u00E9ho ramene 5. chromozomu (del(5q), sledovan\u00FDch \u010Ceskou MDS pracovn\u00ED skupinou. V\u00FDznam pro diagnostick\u00E9 za\u0159azen\u00ED a ur\u010Den\u00ED progn\u00F3zy"@cs . "Smol\u00EDkov\u00E1, A." . "1213-5763" . . "Junov\u00E1, A." . "\u010Cern\u00E1, O." . "4" . "Libiger, J." . "Analysis of myelodysplastic syndrome patients with deletion of long arm of chromosome 5 followed up by the Czech MDS Working Group. Significance for the diagnostic and prognostic assessment"@en . "There are new important discoveries in the pathogenesis and therapy of MDS patients with del(5q). To be well prepared for rational application of new findings for precise diagnosis and new therapy, clinical and laboratory data of our 68 MDS patients with del(5q) were analyzed. Patients were divided into four groups. A ? 5q-syndrome with normal platelet count and B ? with thrombocytemia, C ? patients who did not fulfill two or more out of six criteria of the 5q-syndrome or had thrombocytopenia, D ? patients with further chromosomal aberrations beside del(5q). Sex, age, hematological findings, transfusion dependence and prognostic score (IPSS and WPSS) were evaluated. Survival was calculated in the group of dead patients. AML incidence and time to transformation into AML were also registered. In all 4 groups women prevailed, mostly in the group B. Hypoplastic erythropoiesis predominated in patients with 5q-syndrome and was rare in those of group D. In all groups typical dysplastic megakaryocytes were found. The longest survival was observed in patients of group B ? 5q-syndrome with thrombocythemia. The shortest survival we found in dead patients of group D. Nevertheless, living patients having only one further chromosomal aberration did not differ from those of group A. The incidence of AML was lower compared to the percentage set for MDS in general. AML transformation developed at earliest in patients of group D, at latest in group A and was exceptional in group B. To determine the prognosis of patients with del(5q) as reliably as possible we prefer WPSS to IPSS, we recommend to take in consideration the thrombocytopenia and to try to insert the patients into one of above mentioned groups. To determine the prognosis is especially important for patients of group C and D, because in younger patients with unfavorable prognosis stem cells transplantation needs to be considered."@en . . . "Analysis of myelodysplastic syndrome patients with deletion of long arm of chromosome 5 followed up by the Czech MDS Working Group. Significance for the diagnostic and prognostic assessment"@en . "\u010Cerm\u00E1k, J." . "B\u0159ezinov\u00E1, J." . "Neuwirtov\u00E1, R." . "prognostic assessment; clinical and laboratory picture; del(5q); myelodysplastic syndrome"@en . "Anal\u00FDza nemocn\u00FDch s myelodysplastick\u00FDm syndromem (MDS) s delec\u00ED dlouh\u00E9ho ramene 5. chromozomu (del(5q), sledovan\u00FDch \u010Ceskou MDS pracovn\u00ED skupinou. V\u00FDznam pro diagnostick\u00E9 za\u0159azen\u00ED a ur\u010Den\u00ED progn\u00F3zy"@cs . "RIV/61989592:15110/09:10224439" . . "Transfuze a hematologie dnes" . . "Seifertov\u00E1, N." . . . "V n\u011Bkolika posledn\u00EDch letech do\u0161lo k v\u00FDznamn\u00FDm objev\u016Fm v patogenezi a terapii pacient\u016F s MDS a del(5q). Abychom byli p\u0159ipraveni pro vyu\u017Eit\u00ED nov\u00FDch poznatk\u016F jak pro p\u0159esnou diagn\u00F3zu, tak pro racion\u00E1ln\u00ED indikaci nov\u00E9 l\u00E9\u010Dby (lenalidomid), shrom\u00E1\u017Edili a analyzovali jsme data od 68 nemocn\u00FDch s MDS s cytogenetickou aberac\u00ED del(5q). Osv\u011Bd\u010Dilo se n\u00E1m d\u011Blen\u00ED nemocn\u00FDch do 4 skupin A a\u017E D a to podle toho, jak spl\u0148ovali krit\u00E9ria typick\u00E9ho 5q minus syndromu, p\u0159i \u010Dem\u017E validita 6 krit\u00E9ri\u00ED je nestejn\u00E1. Stoprocentn\u00ED validita plat\u00ED pro p\u0159\u00EDtomnost del(5q) a pro po\u017Eadavek norm\u00E1ln\u00EDho nebo zv\u00FD\u0161en\u00E9ho po\u010Dtu desti\u010Dek pro diagn\u00F3zu 5q minus syndromu. Ve skupin\u011B A a B byli nemocn\u00ED s 5q minus syndromem, a to s norm\u00E1ln\u00EDm po\u010Dtem desti\u010Dek (A) nebo s trombocytemi\u00ED (B). Nemocn\u00ED, kte\u0159\u00ED byli trombocytopeni\u010Dt\u00ED nebo nesplnili 2 a v\u00EDce znak\u016F 5q minus syndromu byli za\u0159azeni do skupiny C. Krit\u00E9ria pro za\u0159azen\u00ED do skupiny D byla dal\u0161\u00ED chromozom\u00E1ln\u00ED aberace krom\u011B del(5q)." . . "Michalov\u00E1, K." . "18"^^ . . "Hochov\u00E1, I." . . "RIV/61989592:15110/09:10224439!RIV12-MSM-15110___" . "V n\u011Bkolika posledn\u00EDch letech do\u0161lo k v\u00FDznamn\u00FDm objev\u016Fm v patogenezi a terapii pacient\u016F s MDS a del(5q). Abychom byli p\u0159ipraveni pro vyu\u017Eit\u00ED nov\u00FDch poznatk\u016F jak pro p\u0159esnou diagn\u00F3zu, tak pro racion\u00E1ln\u00ED indikaci nov\u00E9 l\u00E9\u010Dby (lenalidomid), shrom\u00E1\u017Edili a analyzovali jsme data od 68 nemocn\u00FDch s MDS s cytogenetickou aberac\u00ED del(5q). Osv\u011Bd\u010Dilo se n\u00E1m d\u011Blen\u00ED nemocn\u00FDch do 4 skupin A a\u017E D a to podle toho, jak spl\u0148ovali krit\u00E9ria typick\u00E9ho 5q minus syndromu, p\u0159i \u010Dem\u017E validita 6 krit\u00E9ri\u00ED je nestejn\u00E1. Stoprocentn\u00ED validita plat\u00ED pro p\u0159\u00EDtomnost del(5q) a pro po\u017Eadavek norm\u00E1ln\u00EDho nebo zv\u00FD\u0161en\u00E9ho po\u010Dtu desti\u010Dek pro diagn\u00F3zu 5q minus syndromu. Ve skupin\u011B A a B byli nemocn\u00ED s 5q minus syndromem, a to s norm\u00E1ln\u00EDm po\u010Dtem desti\u010Dek (A) nebo s trombocytemi\u00ED (B). Nemocn\u00ED, kte\u0159\u00ED byli trombocytopeni\u010Dt\u00ED nebo nesplnili 2 a v\u00EDce znak\u016F 5q minus syndromu byli za\u0159azeni do skupiny C. Krit\u00E9ria pro za\u0159azen\u00ED do skupiny D byla dal\u0161\u00ED chromozom\u00E1ln\u00ED aberace krom\u011B del(5q)."@cs . . . . "Kadl\u010Dkov\u00E1, E." . "[4D4AA386181C]" . "B\u011Blohl\u00E1vkov\u00E1, P." . . "Mikulenkov\u00E1, D." . "Vondr\u00E1kov\u00E1, Jana" . "\u0160i\u0161kov\u00E1, M." . "1"^^ . "CZ - \u010Cesk\u00E1 republika" . . . "I, V, Z(MSM0021620808)" . "Anal\u00FDza nemocn\u00FDch s myelodysplastick\u00FDm syndromem (MDS) s delec\u00ED dlouh\u00E9ho ramene 5. chromozomu (del(5q), sledovan\u00FDch \u010Ceskou MDS pracovn\u00ED skupinou. V\u00FDznam pro diagnostick\u00E9 za\u0159azen\u00ED a ur\u010Den\u00ED progn\u00F3zy" . "303138" . "Anal\u00FDza nemocn\u00FDch s myelodysplastick\u00FDm syndromem (MDS) s delec\u00ED dlouh\u00E9ho ramene 5. chromozomu (del(5q), sledovan\u00FDch \u010Ceskou MDS pracovn\u00ED skupinou. V\u00FDznam pro diagnostick\u00E9 za\u0159azen\u00ED a ur\u010Den\u00ED progn\u00F3zy" . . "Vozobulov\u00E1, V." . "Jon\u00E1\u0161ov\u00E1, A." . "6"^^ . "15" . "15110" .